<DOC>
	<DOCNO>NCT02729025</DOCNO>
	<brief_summary>A study assess effect proprotein convertase subtilisin/ kexin type 9 ( PCSK9 ) inhibition arterial wall inflammation patient elevate lipoprotein ( ) .</brief_summary>
	<brief_title>Effects Proprotein Convertase Subtilisin/Kexin Type 9 ( PCSK9 ) Inhibition Arterial Wall Inflamation Study Patients With Elevated Lipoprotein ( ) ( Lp ( ) ) .</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Fasting lipoprotein ( ) ( Lp ( ) ) 50mg/dL screen 1 Fasting Lowdensity lipoproteincholesterol ( LDLC ) 100mg/dL screen 1 Lipid lower therapy include statin dose unchanged least 8 week prior screen Targettobackground ratio ( TBR ) max high 1.6 ( either right , leave carotid thoracic aorta ) fluorodeoxyglucosepositron emission tomography/computed tomography ( FDGPET/CT ) . Currently receive , less 4 week since receiving , treatment another investigational device drug study ( y ) , participate investigational procedure Known diagnosis diabetes mellitus screen fast serum glucose ≥ 126 mg/dL hemoglobin A1C ( HbA1C ) ≥ 6.5 % Subject history homozygous familial hypercholesterolemia History Cardiovascular event Subject currently undergo lipid apheresis Known contraindication limitation FDGPET/ CT ( scanner weight limit , device cause image artifact , carotid/aortic stents/grafts Subject exposure investigational drug target Lp ( ) within last 12 month , prior Screening Other Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) Inhibition</keyword>
	<keyword>Arterial Wall Inflamation</keyword>
	<keyword>Elevated lipoprotein</keyword>
</DOC>